EPID-01. GLIOBLASTOMA TREATMENT OF BEVACIZUMAB ERA IN KANSAI REGION, JAPAN

Randomized trials failed to prove the efficacy of Bevacizumab on OS of newly diagnosed glioblastomas, but improvement of PFS was revealed. Based on these results, Japanese national health insurance approved Bevacizumab (Bev) for both primary and recurrent glioblastoma treatment in 2013. And at same...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Mori, Kanji, Shofuda, Tomoko, Okita, Yoshiko, Arita, Hideyuki, Kinoshita, Manabu, Terakawa, Yuzo, Tsuyuguchi, Naohiro, Tomogane, Yusuke, Fukai, Junya, Ishibashi, Kenichi, Nishida, Namiko, Taki, Takuyu, Nonaka, Masahiro, Izumoto, Shuichi, Moriuchi, Shusuke, Nakajima, Yoshikazu, Hashimoto, Naoya, Kodama, Yoshinori, Hirose, Takanori, Kanemura, Yonehiro
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5693178/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.279
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares